Synonyms: TNFSF13B, CD257
Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Name | Citation | CD38 | CD45 | CD39 | CD88 | CD73 | Others |
|---|---|---|---|---|---|---|---|
| RBN013209 | 0 | ||||||
| MK-0159 | 0 | ||||||
| CD38 inhibitor 1 (compound 78c) | 7 | ||||||
| AB680 | 1 | ||||||
| NQ301 | 1 | TXA2 receptor | |||||
| SodiuM Metatungstate | 3 | ||||||
| PMX-53 | 3 | ||||||
| LY-3475070 | 2 |
| Description |
Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa.
|
|---|
| CAS No. | 356547-88-1 |
|---|---|
| Molecular Weight | 144.56 kDa |
| Isotype | Human IgG1 |
| Source | CHO |
| Purification | AKTA |
| Sterility | 0.2 μM filtered |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06191887 | RECRUITING | Drug: Bendamustine|Drug: Cyclophosphamide|Drug: Fludarabine | B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Recurrent Transformed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Diffuse Large B-Cell Lymphoma; Refractory Follicular Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Small Lymphocytic Lymphoma; Refractory Transformed Chronic Lymphocytic Leukemia | Mayo Clinic | 2024-03-18 | PHASE1 |
| NCT07771361 | NOT_YET_RECRUITING | Non-Hodgkin Lymphoma Refractory/ Relapsed; Multiple Myeloma Refractory; Multiple Myeloma in Relapse; Non-Hodgkin Lymphoma, B-cell; Non-Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma; Multiple Myeloma in Remission | Luminary Therapeutics | 2026-12 | PHASE2 | |
| NCT07729995 | NOT_YET_RECRUITING | Rheumatoid Arthritis (RA); Systemic Lupus Erthematosus (SLE); Dermatomyositis (DM); Systemic Sclerosis (SSc) | Luminary Therapeutics | 2026-10 | PHASE1 | |
| NCT06716606 | RECRUITING | Drug: Belimumab | Connective Tissue Diseases | GlaxoSmithKline | 2024-12-12 | PHASE3 |
| NCT07259070 | RECRUITING | Drug: BAFF-R CAR-T | DLBCL; CLL; FL; MCL; WM; MZL | Institute of Hematology & Blood Diseases Hospital, China | 2025-11-29 | PHASE1; PHASE2 |
| NCT05878717 | RECRUITING | Systemic Sclerosis Associated Interstitial Lung Disease; Scleroderma, Systemic | GlaxoSmithKline | 2023-09-13 | PHASE2; PHASE3 |
(data from https://clinicaltrials.gov, updated on 2026-02-13)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.